Sign in

    Jeff Meacham

    Managing Director and Senior Equity Analyst at Citigroup Inc.

    Geoff Meacham is a Managing Director and Senior Equity Analyst at Citigroup Inc., specializing in biotechnology and pharmaceutical sector research. He covers key companies including Protagonist Therapeutics, Biogen, Pfizer, and Acumen Pharmaceuticals, consistently delivering actionable ratings, with recent metrics showing an analyst accuracy rate of 61% on platforms like TipRanks and a performance track record aligning with consensus 'Strong Buy' recommendations. Meacham began his analyst career in the early 1990s, holding senior roles at leading financial firms and joined Citi as Managing Director in September 2024, leveraging over two decades of industry experience. Holding a PhD from the University of Alabama at Birmingham and a BS from the University of Georgia, he maintains professional registration with FINRA and is licensed for securities research.

    Jeff Meacham's questions to Acumen Pharmaceuticals (ABOS) leadership

    Jeff Meacham's questions to Acumen Pharmaceuticals (ABOS) leadership • Q2 2025

    Question

    An analyst on behalf of Jeff Meacham inquired about physician feedback on the use of pTau217 blood testing during the screening process for Alzheimer's patients.

    Answer

    Chief Medical Officer Dr. Eric Siemers stated that using pTau217 testing in the ALPITUDE study was highly effective, reducing the PET scan screen failure rate from over 60% to 17% and cutting screening costs by approximately 40%. He reported positive feedback from clinicians, noting that the FDA-approved test is expanding the diagnostic pipeline, with adoption seen even among primary care physicians.

    Ask Fintool Equity Research AI

    Jeff Meacham's questions to NOVAVAX (NVAX) leadership

    Jeff Meacham's questions to NOVAVAX (NVAX) leadership • Q2 2025

    Question

    On behalf of Jeff Meacham at Citigroup, an analyst asked how the push for a universal vaccine might impact partnership discussions for Novavax's flu and CIC candidates. They also inquired how the company plans to fund its expansion into new areas like oncology, based on projected cash flow from the Sanofi collaboration.

    Answer

    President, CEO & Director John Jacobs dismissed concerns about a universal vaccine, noting it has been an unsuccessful scientific endeavor for decades and does not impede current partnership talks. EVP, CFO & Treasurer Jim Kelly addressed funding, explaining the strategy is not for Novavax to become an oncology company, but to generate compelling data to encourage oncology-focused firms to license its Matrix-M adjuvant. Jacobs confirmed that these exploratory R&D efforts are fully accounted for within the company's current lean financial plan.

    Ask Fintool Equity Research AI

    Jeff Meacham's questions to ELI LILLY & (LLY) leadership

    Jeff Meacham's questions to ELI LILLY & (LLY) leadership • Q4 2024

    Question

    Jeff Meacham of Citigroup asked if positive data for tirzepatide in broader settings, like diabetes prevention or a successful CVOT, would be a tipping point for reimbursement.

    Answer

    Executive Patrik Jonsson noted such data would help drive employer opt-in. CEO David Ricks added that reimbursement will grow steadily from an accumulation of data over time, not from a single event, though these data sets would be compelling.

    Ask Fintool Equity Research AI